The management of thyroid and parathyroid cancer

Nasheed M. Hossain, Colleen Veloski, Ranee Mehra

Research output: Chapter in Book/Report/Conference proceedingChapter


Thyroid and parathyroid cancers are both relatively uncommon malignancies; however, the yearly incidence of thyroid cancer has nearly tripled since 1975. The mainstay of treatment of these endocrine malignancies has been surgical resection and radioactive iodine treatment for thyroid cancer. Differentiated thyroid cancers encompass papillary and follicular carcinomas and are responsive to radioactive iodine treatment and TSH suppression, in contrast to medullary thyroid cancer. There is now a greater understanding of the molecular pathogenesis of differentiated thyroid cancers, poorly differentiated and anaplastic thyroid cancers, and medullary thyroid cancer. This has prompted numerous phase studies utilizing oral biologically targeted agents that inhibit a variety of tyrosine kinase inhibitors, such as the vascular endothelial growth factor receptors, c-Kit, RET, and PDGFR. This review will discuss the epidemiology, histologies, pathogenesis, and issues in management of thyroid and parathyroid cancers.

Original languageEnglish (US)
Title of host publicationHead and Neck Cancer
Subtitle of host publicationMultimodality Management, Second Edition
PublisherSpringer International Publishing
Number of pages20
ISBN (Electronic)9783319276014
ISBN (Print)9783319275994
StatePublished - Jan 1 2016


  • Parathyroid cancer
  • Thyroid cancer
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The management of thyroid and parathyroid cancer'. Together they form a unique fingerprint.

Cite this